TABLE 1

HPLC/MS/MS conditions for all 13 compounds

Compound
Retention Time (min)
MRM Transition
Initial Condition
Final Condition
Column
Caffeine 1.03 195.2:138.1 70% A/30% B 70% A/30% B Luna Phenyl Hexyl 5 × 4.6, 5 μa
CP-141938 1.40 404.3:160.2 25% A/75% B 25% A/75% B Synergi Polar RP 5 × 4.6, 4 μa
Fluoxetine 2.80 310.1:148.1 90% A/10% B 10% A/90% B Primesphere C18 3 × 2, 5 μa
Midazolam 1.48 326.2:291.1 25% A/75% B 25% A/75% B Synergi Polar RP 5 × 4.6 4 μa
NFPS 3.66 394.0:102.1 90% A/10% B 10% A/90% B Primesphere C18 3 × 2, 5 μa
Propranolol 3.48 260.1:116.2 90% A/10% B 10% A/90% B Primesphere C18 3 × 2, 5 μa
Quinidine 2.83 325.3:307.4 90% A/10% B 10% A/90% B Ace C18 5 × 4.6, 5 μb
Theobromine 1.10 181.1:138.2 25% A/50% B/25% C 25% A/50% B/25% C Ace C18 5 × 4.6, 5 μb
Theophylline 1.25 181.1:124.1 25% A/75% B 25% A/7/5% B Ace C18 5 × 4.6, 5 μb
Thiopental 1.16 241.4:101.0 25% A/75% B 25% A/75% B Synergi Polar RP 5 × 4.6, 4 μa
Sulpiride 1.61 342.0:112.1 25% A/75% B 25% A/75% B Synergi Polar RP 5 × 4.6, 4 μa
Zolpidem 1.46 308.2:235.2 25% A/75% B 25% A/75% B Synergi Polar RP 5 × 4.6, 4 μa
9-OH Risperidone
1.15
427.2:207.2
25% A/75% B
25% A/75% B
Synergi Polar RP 50 × 4.6, 4 μa

  • 9-OH risperidone, 9-hydroxyrisperidone; A, ammonium acetate buffer at pH 7.0; B, acetonitrile; C, methanol; MRM, multiple reaction monitoring.

  • ↵ a Phenomenex, Torrance, CA.

  • ↵ b MAC-MOD Analytical, Inc., Chadds Ford, PA.